Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04624451 · ClinicalTrials.gov registry record
Evaluation of Intravenous Dalbavancin for Peritonitis
A clinical trial, sponsored by University of Colorado, Denver.
- Terminated
- Registry status
- 2
- Enrollment target
NCT04624451 is a clinical trial that was terminated before completion, run by University of Colorado, Denver. The registered enrollment target is 2 participants.
The verdict
NCT04624451 was terminated before completion, sponsored by University of Colorado, Denver.
- TERMINATED
- Registry status
- 2 participants
- Enrollment target
Study Summary
This study evaluates the use of Dalbavancin 1500 mg IV x 1 dose for treating patients with gram positive peritonitis in patients requiring peritoneal dialysis.
Interventions
- DRUG Dalbavancin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2020-06-01 |
| Est. Completion | 2024-01-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04624451
The ClinicalTrials.gov registry entry for NCT04624451 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dalbavancin is the first listed.
NCT04624451 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04624451 about?
NCT04624451 is a clinical study titled "Evaluation of Intravenous Dalbavancin for Peritonitis". This study evaluates the use of Dalbavancin 1500 mg IV x 1 dose for treating patients with gram positive peritonitis in patients requiring peritoneal dialysis.
What is the current status of trial NCT04624451?
This trial is currently terminated. The enrollment target is 2 participants. The study started on 2020-06-01. Estimated completion is 2024-01-31.
What interventions are being tested in trial NCT04624451?
The interventions under investigation include: Dalbavancin (DRUG).
Who is sponsoring clinical trial NCT04624451?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.